Table 1.
Characteristics of patients between groups
| Characteristic (median, range) | Cinvanti (n = 101) | Emend IV (n = 101) | Generic alternatives (n = 92) |
|---|---|---|---|
| Patient age | 60 (21 to 82) | 59 (22 to 82) | 62 (25 to 80) |
| Female sex | 77.2% | 81.2% | 62.0% |
| BMI | 28.5 (16.2 to 49.6) | 29.7 (16.2 to 52) | 29.0 (16.6 to 48) |
| Race | |||
| White | 69.3% | 80.2% | 69.6% |
| Black | 10.9% | 4.0% | 4.4% |
| Other | 5.0% | 3.0% | 1.1% |
| Not documented | 14.8% | 12.9% | 25.0% |
| Cancer diagnosis | |||
| Breast | 43.6% | 49.5% | 31.5% |
| Lung | 12.9% | 8.9% | 13.0% |
| Gynecological | 14.8% | 14.8% | 2.3% |
| Colorectal | 10.9% | 5.0% | 16.3% |
| Other | 17.8% | 21.8% | 36.9% |
| Disease stage | |||
| I–III | 67.3% | 72.3% | 64.1% |
| IV | 21.8% | 20.8% | 26.1% |
| Not documented | 10.9% | 6.9% | 9.8% |
| ECOG | |||
| 0 | 47.5% | 55.4% | 63.0% |
| 1 | 32.7% | 31.7% | 27.2% |
| ≥ 2 | 5.9% | 7.9% | 3.3% |
| Not documented | 13.9% | 5.0% | 6.5% |
| Charlson comorbidity score | 3 (2 to 10) | 3 (2 to 13) | 4 (2 to 16) |
| Active diabetes1 | 11.9% | 10.9% | 26.1% |
| Prior fosaprepitant | 4.0% | 2.0% | 2.2% |
Abbreviations: IV intravenous, BMI body mass index, ECOG Easter Cooperative Oncology Group performance status
1Define as patients who were receiving anti-diabetic medication